AISAP Cardio vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 70/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Both AISAP Cardio and EchoGo Amyloidosis are FDA-cleared, AI-powered cardiology tools that analyze echocardiogram data. However, AISAP Cardio offers a comprehensive suite for general cardiac diagnostic assessments, including structural heart disease and heart failure, while EchoGo Amyloidosis is highly specialized for the early detection of cardiac amyloidosis. The choice between them depends on the need for broad cardiac assessment versus targeted screening for a specific condition.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
AISAP Cardio is an AI-powered POCUS software platform designed for rapid, comprehensive cardiac diagnostic assessments and measurements, enabling early detection of structural heart disease and heart failure at the bedside. In contrast, EchoGo Amyloidosis is an AI-powered screening tool specifically for analyzing echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
AISAP Cardio assesses valvular pathologies such as mitral, tricuspid, and aortic regurgitation, and aortic stenosis, along with measurements of Left Ventricle Ejection Fraction (LVEF), ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter. EchoGo Amyloidosis identifies suspected cardiac amyloidosis, providing a diagnostic output of 'suggestive' or 'not suggestive' of the condition, and analyzes echocardiographic markers like ventricular volume, cardiac function, and myocardial movement.
AISAP Cardio's pricing is not publicly available, requiring direct contact for demo and pricing information. EchoGo Amyloidosis has publicly available pricing details, including specific NTAP codes for inpatient analyses (Medicare-covered at $1,000 per analysis) and HCPCS codes for outpatient analyses (covered by Medicare and select commercial insurers at $285 per analysis).
Both AISAP Cardio and EchoGo Amyloidosis are cloud-based SaaS platforms designed for seamless integration. They integrate with existing clinical workflows, EHR/EMR, PACS, DICOM, and HL7 systems.
EchoGo Amyloidosis has demonstrated high diagnostic accuracy, achieving 85% sensitivity and 93% specificity in detecting cardiac amyloidosis. It has also shown consistent performance across various cardiac amyloidosis subtypes, including AL, wild-type ATTR, and variant ATTR.